Functional polymorphisms in theLDLRand pharmacokinetics of Factor VIII concentrates-Reference-Cited by-同舟云学术

Functional polymorphisms in theLDLRand pharmacokinetics of Factor VIII concentrates

Published:2019-05-29 Issue:8 Volume:17 Page:1288-1296
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Lunghi Barbara¹,Bernardi Francesco¹^ORCID,Martinelli Nicola²^ORCID,Frusconi Sabrina³,Branchini Alessio¹,Linari Silvia⁴,Marchetti Giovanna⁵,Castaman Giancarlo⁴,Morfini Massimo⁶

Affiliation:

1. Department of Life Sciences and Biotechnology University of Ferrara Ferrara Italy

2. Department of Medicine University of Verona Verona Italy

3. Genetic Diagnostics Unit, Laboratory DepartmentCareggi University Hospital Florence Italy

4. Center for Bleeding Disorders Department of Oncology Careggi University Hospital Florence Italy

5. Department of Biomedical and Specialty Surgical Sciences University of Ferrara Ferrara Italy

6. Italian Association Hemophilia Centers (AICE) Milan Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14473

Reference36 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

3. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs

4. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels

5. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Thrombo-inflammation in Ischemic Stroke: Focus on the Manipulation and Clinical Application;Molecular Neurobiology;2024-08-06

2. Binding Promiscuity of Therapeutic Factor VIII;Thrombosis and Haemostasis;2024-07-01

3. Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers;BLOOD TRANSFUS-ITALY;2023

4. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF–FVIII clearance in thrombosis and hemostasis;Journal of Thrombosis and Haemostasis;2023-08

5. Managing Relevant Clinical Conditions of Hemophilia A/B Patients;Hematology Reports;2023-06-07